// App-Quantinova.ai

TPS4619 : CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570).

Researchers

Presenter

  • Wassim Kassouf

Principal Investigators

  • Simon J. Crabb

  • Ignacio Duran

  • Michael Donald Brundage

  • M. Neil Reaume

  • Alice Dragomir

  • Alexander William Wyatt

  • Francisco Emilio Vera Badillo

  • Himu Lukka

  • Tamim Niazi

  • Luis Souhami

  • Srikala S. Sridhar

  • Gareth Owen Griffiths

  • Doris Howell

  • Harriet Richardson

  • Marina Djurfeldt

  • Keyue Ding

  • Wendy R. Parulekar

Medical Centers

  • McGill University Health Centre, Montreal, QC, Canada

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

  • Department of Radiology, H. Universitario Marques de Valdecilla, Santander, Spain

  • Division of Cancer Care & Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON, Canada

  • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • Montreal University, Montreal, QC, Canada

  • Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Juravinski Cancer Centre, Burlington, ON, Canada

  • Jewish General Hospital/ McGill Univeristy, Montreal, QC, Canada

  • McGill University Health Centre, Montreal, QC, Canada

  • Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • University of Southampton, Southampten, United Kingdom

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

Locations

  • Canada

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Durvalumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT03768570

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved